| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/23/2002 | US6376481 Solid oral dosage form comprising support having given surface area range such as silicon dioxide, a stanol ester to reduce cholesterol, and a mixed micelle surfactant system |
| 04/23/2002 | US6376480 Vitamin D derivatives with substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agents |
| 04/23/2002 | US6376476 Isoprenoid pathway inhibitors for stimulating bone growth |
| 04/23/2002 | US6376464 That form amphipathic helices, bind lipids, form prebeta-like or hdl-like complexes, activate lcat, increase serum levels of hdl fractions, and promote cholesterol efflux, dyslipopro-teinemia, hypercholesterolemia, cardiovascular disorders |
| 04/23/2002 | US6376242 Reduce the number of circulating platelets to low or below normal levels. |
| 04/23/2002 | US6375975 Pharmaceutical compositions for buccal and pulmonary application |
| 04/23/2002 | US6375950 Methods for inducing T cell unresponsiveness to donor tissue or organ in a recipient with gp39 antagonists |
| 04/23/2002 | CA2229504C Flavanone-containing composition |
| 04/23/2002 | CA2191714C Therapeutic food composition and method to diminish blood sugar fluctuations |
| 04/23/2002 | CA2047389C Substituted piperidines and their use as inhibitors of cholesterol synthesis |
| 04/18/2002 | WO2002031498A2 Protecting therapeutic compositions from host-mediated inactivation |
| 04/18/2002 | WO2002031145A1 Novel g protein-coupled receptor protein and dna thereof |
| 04/18/2002 | WO2002031134A2 Novel serine protease genes related to dppiv |
| 04/18/2002 | WO2002031115A2 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | WO2002031109A2 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | WO2002030938A1 Benzhydryl derivatives |
| 04/18/2002 | WO2002030924A1 Quinazoline derivatives with anti-tumour activity |
| 04/18/2002 | WO2002030923A1 Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 04/18/2002 | WO2002030914A1 Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them |
| 04/18/2002 | WO2002030911A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | WO2002030908A1 Inhibitors of protein kinases |
| 04/18/2002 | WO2002030904A1 Pyridinone derivatives for treatment of atherosclerosis |
| 04/18/2002 | WO2002030902A1 Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine.hydrochloride |
| 04/18/2002 | WO2002030895A1 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS |
| 04/18/2002 | WO2002030890A1 Nitrogenous five-membered ring compounds |
| 04/18/2002 | WO2002030884A2 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030882A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030876A2 Cyclic carboxylic acids as integrin antagonists |
| 04/18/2002 | WO2002030875A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | WO2002030874A2 Aliphatic, cyclic amino carboxylic acids as integrin antagonists |
| 04/18/2002 | WO2002030867A2 Drugs for diabetes |
| 04/18/2002 | WO2002030863A2 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030860A2 Ketone compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030431A1 Obesity regulatory compositions |
| 04/18/2002 | WO2002030428A1 Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments |
| 04/18/2002 | WO2002030418A1 Compositions for improving lipid metabolism |
| 04/18/2002 | WO2002030415A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 04/18/2002 | WO2002030414A1 Compositions comprising modafinil compounds |
| 04/18/2002 | WO2002030353A2 NF-λB INHIBITORS |
| 04/18/2002 | WO2002030213A1 Encased food product with contrasting components |
| 04/18/2002 | WO2002017914A3 Fused pyrrolocarbazoles against inflammation |
| 04/18/2002 | WO2002012210A9 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 04/18/2002 | WO2002009815A3 New pharmaceutical composition |
| 04/18/2002 | WO2002009814A3 New use of lipase inhibitors |
| 04/18/2002 | WO2002008217A3 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 04/18/2002 | WO2002002541A3 Inhibitors of copper-containing amine oxidases |
| 04/18/2002 | WO2001082952A3 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS |
| 04/18/2002 | WO2001072777A3 Human transcription factors |
| 04/18/2002 | WO2001068075A3 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 04/18/2002 | WO2001061007A9 Fibroblast growth factor-23 molecules and uses thereof |
| 04/18/2002 | WO2001060377A3 Methods for treatment of lysosomal storage diseases using biphosphonates |
| 04/18/2002 | WO2001060152A3 Transgenic non-human ucp2 knockout mammal |
| 04/18/2002 | WO2001026656A3 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
| 04/18/2002 | WO2001005253A8 Compositions, kits, and methods for providing and maintaining energy and mental alertness |
| 04/18/2002 | WO2000068385A9 Novel nucleic acids and proteins with growth hormone activity |
| 04/18/2002 | WO2000061177A9 Composition based on oppositely-charged polypeptides |
| 04/18/2002 | US20020045777 Used to treat hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes. |
| 04/18/2002 | US20020045652 Prophylactic or therapeutic drug for renal diseases |
| 04/18/2002 | US20020045645 Lactone integrin antagonists |
| 04/18/2002 | US20020045635 Novel mGluR antagonists and a method for their synthesis |
| 04/18/2002 | US20020045630 Antiproliferative, -carcinogenic, -tumor and -diabetic agents; binding to or modulating the human kinase insert-domain-containing receptor (KDR) or the murine fetal liver kinase 1 (FLK-1) receptor; vasculogenesis; angiogenesis |
| 04/18/2002 | US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders. |
| 04/18/2002 | US20020045620 Readily metabolized by the metabolic drug detoxification systems; metabolized by serum or intracellular hydrolases and esterases; shorthalf-life; noninsulin-dependent diabetes mellitus (NIDDM) (Type II); side effect reduction |
| 04/18/2002 | US20020045613 1-aroyl-piperidinyl benzamidines |
| 04/18/2002 | US20020045596 Aging resistance; oxidation resistance |
| 04/18/2002 | US20020045595 N6 heterocyclic 8-modified adenosine derivatives |
| 04/18/2002 | US20020045572 Method of treating the syndrome of type 2 diabetes in humans |
| 04/18/2002 | US20020045568 Use of mp52 0r mp121 for treating and preventing diseases of the nervous system |
| 04/18/2002 | US20020045264 Expression vectors for use in gene therapy |
| 04/18/2002 | US20020044981 Mixture of polyunsaturated fatty acids containing linoleic, gamma-linolenic, alpha-linolenic, and stearidonic acid; antilipemic agent, antioxidant and/or antidiabetic agent. |
| 04/18/2002 | DE10050663A1 Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases |
| 04/18/2002 | CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
| 04/18/2002 | CA2425773A1 Compositions for improving lipid metabolism |
| 04/18/2002 | CA2425678A1 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425672A1 Use of substituted imidazo[1,2-a]-pyridin-,pyrimidin-and -pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting nos |
| 04/18/2002 | CA2425655A1 Drugs for diabetes |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425540A1 Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine.hydrochloride |
| 04/18/2002 | CA2425407A1 Protecting therapeutic compositions from host-mediated inactivation |
| 04/18/2002 | CA2425121A1 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425001A1 Novel serine protease genes related to dppiv |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424951A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | CA2424928A1 Encased food product with contrasting components |
| 04/18/2002 | CA2424802A1 Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 04/18/2002 | CA2422744A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 04/18/2002 | CA2394084A1 Inhibitors of protein kinases |
| 04/17/2002 | EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 04/17/2002 | EP1197496A1 Novel peptides |
| 04/17/2002 | EP1197493A1 Benzimidazole compounds |
| 04/17/2002 | EP1197487A1 Benzimidazole compounds and drugs containing the same |
| 04/17/2002 | EP1197484A2 1H-Indole-3-glyoxylamide sPLA2 inhibitors |
| 04/17/2002 | EP1197225A1 REMEDIES FOR DISEASES CAUSED BY PTH OR PTHrP |
| 04/17/2002 | EP1196783A2 Screening for therapeutic agents being scap antagonists |
| 04/17/2002 | EP1196598A1 Dsp-3 dual-specificity phosphatase |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |